Aura Biosciences, Inc. (AURA) Current Ratio
- Current ratio · latest quarter: Value 16.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.82× | Current assets / current liabilities. $329.03M ÷ $19.56M ≈ 16.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 329.03M USD | Assets, Current |
| Current obligations | 19.56M USD | Liabilities, Current |
| Cash and equivalents | 67.84M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.25M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $329.03M | $19.56M | $67.84M | (m) | (m) | (m) | $2.25M | (m) | 16.82× |
| 2026-03-31 | $118.50M | $16.71M | $84.79M | (m) | (m) | (m) | $2.57M | (m) | 7.09× |
| 2025-12-31 | $149.74M | $18.38M | $59.52M | (m) | (m) | (m) | $1.55M | (m) | 8.15× |
| 2025-09-30 | $170.12M | $18.82M | $47.55M | (m) | (m) | (m) | $1.89M | (m) | 9.04× |
| 2025-06-30 | $183.96M | $14.85M | $107.37M | (m) | (m) | (m) | $1.29M | (m) | 12.39× |
| 2025-03-31 | $134.52M | $12.16M | $38.23M | (m) | (m) | (m) | $2.01M | (m) | 11.06× |
| 2024-12-31 | $160.62M | $14.91M | $31.69M | (m) | (m) | (m) | $2.30M | (m) | 10.77× |
| 2024-09-30 | $183.48M | $14.71M | $25.41M | (m) | (m) | (m) | $1.99M | (m) | 12.47× |
| 2024-06-30 | $195.60M | $10.55M | $30.07M | (m) | (m) | (m) | $1.46M | (m) | 18.54× |
| 2024-03-31 | $212.25M | $9.66M | $26.28M | (m) | (m) | (m) | $1.93M | (m) | 21.97× |
| 2023-12-31 | $231.79M | $12.36M | $41.06M | (m) | (m) | (m) | $1.79M | (m) | 18.76× |
| 2023-09-30 | $153.89M | $10.89M | $55.58M | (m) | (m) | (m) | $1.49M | (m) | 14.13× |
| 2023-06-30 | $166.21M | $8.89M | $47.73M | (m) | (m) | (m) | $553.00K | (m) | 18.69× |
| 2023-03-31 | $179.12M | $8.11M | $38.49M | (m) | (m) | (m) | $1.05M | (m) | 22.09× |
| 2022-12-31 | $196.70M | $10.46M | $121.58M | (m) | (m) | (m) | $2.92M | (m) | 18.81× |
| 2022-09-30 | $115.91M | $9.96M | $61.11M | (m) | (m) | (m) | $1.72M | (m) | 11.63× |
| 2022-06-30 | $127.67M | $5.81M | $53.85M | (m) | (m) | (m) | $1.20M | (m) | 21.97× |
| 2022-03-31 | $139.58M | $5.00M | $108.38M | (m) | (m) | (m) | $1.96M | (m) | 27.90× |
| 2021-12-31 | $153.70M | $7.36M | $149.06M | (m) | (m) | (m) | $2.40M | (m) | 20.90× |
| 2021-09-30 | $83.46M | $5.83M | $81.83M | (m) | (m) | (m) | $1.74M | (m) | 14.31× |
| 2020-12-31 | $18.45M | $2.66M | $17.39M | (m) | (m) | (m) | $611.00K | (m) | 6.94× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |